These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 19381089)

  • 1. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antivasoproliferative agents in ophthalmology].
    Ambresin A; Zografos L; Mantel I
    Rev Med Suisse; 2010 Jan; 6(231):51-4. PubMed ID: 20196434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGF agents for age-related macular degeneration.
    Ozkiris A
    Expert Opin Ther Pat; 2010 Jan; 20(1):103-18. PubMed ID: 20021287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vascular endothelial growth factor in ocular angiogenesis.
    Shams N; Ianchulev T
    Ophthalmol Clin North Am; 2006 Sep; 19(3):335-44. PubMed ID: 16935208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of retinal diseases with VEGF antagonists.
    Schlingemann RO; Witmer AN
    Prog Brain Res; 2009; 175():253-67. PubMed ID: 19660661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M
    Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for the treatment of ocular neovascularization.
    Bradley J; Ju M; Robinson GS
    Angiogenesis; 2007; 10(2):141-8. PubMed ID: 17372853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-macular degeneration agents.
    Rothen M; Jablon E; Monares G; Fontal MR; Alfaro DV
    Ophthalmol Clin North Am; 2005 Dec; 18(4):561-7. PubMed ID: 16314219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
    Andreoli CM; Miller JW
    Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy using the small interfering RNA bevasiranib.
    Singerman L
    Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J; Ruiz-Moreno JM; Martín-Ventura JL; Blanco-Colio LM; Lorenzo O; Egido J
    Surv Ophthalmol; 2009; 54(3):339-48. PubMed ID: 19422962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
    Canavese M; Altruda F; Ruzicka T; Schauber J
    J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH; Luo J; Zhang K; Zhang M
    Discov Med; 2013 Jun; 15(85):343-8. PubMed ID: 23819948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factors in retinal and choroidal neovascular diseases.
    Kinnunen K; Ylä-Herttuala S
    Ann Med; 2012 Feb; 44(1):1-17. PubMed ID: 21284527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor biology: clinical implications for ocular treatments.
    Bhisitkul RB
    Br J Ophthalmol; 2006 Dec; 90(12):1542-7. PubMed ID: 17114590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.